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ABSTRACT
Introduction: The central diagnostic feature of
rosacea is diffuse central-facial erythema. The
objective was to summarize published and
unpublished health-related quality of life
(HRQoL) data from seven previous studies in
rosacea patients.
Methods: A meta-analysis was performed on
baseline HRQoL data of subjects with erythema
of rosacea from five randomized controlled
trials, one open-label safety study and one
epidemiological study. The data from four
questionnaires were analyzed, including the
Euro QoL 5-dimension (EQ5D) generic
questionnaire, the Dermatology Life Quality
Index (DLQI) dermatology-specific quality of
life instrument, the Productivity and Social Life
Questionnaire and the Facial Redness
Questionnaire.
Results: The global EQ5D index score was
0.859 and the domains of pain/discomfort
(31.5% moderate or extreme pain) and
anxiety/depression (26.4% moderate or
extreme) were most affected. Worse scores
were observed with erythema of rosacea in the
absence of inflammatory lesions (EQ5D score of
0.832 for no lesions vs 0.919 for subjects with
C1 lesion). Almost half (43%) the subjects had
at least moderately impaired HRQoL, including
19.8% with a DLQI total score of C11 indicating
severely impaired HRQoL; symptoms/feelings
was the most affected domain. Subjects with a
patient self-assessment (PSA) of severe erythema
of rosacea had a worse mean DLQI score than
moderate PSA subjects (8.6 vs 6.0). Work life
and social life were affected, especially in
subjects with severe PSA (62% with social life
at least somewhat affected).
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INTRODUCTION
Rosacea is a common chronic inflammatory
skin disease causing flushing, redness, red
pimples and pustules on the face [1].
Furthermore, symptoms of rosacea may lead to
physical discomfort (e.g., burning and stinging)
and may have considerable psychosocial impact
causing embarrassment, anxiety and low
self-esteem among patients [2]. As erythema or
facial redness is clearly visible, it is one of the
main factors contributing to low health-related
quality of life (HRQoL) in rosacea patients [3].
It has been reported that some clinicians
consider erythema of rosacea as mainly a
cosmetic problem and underestimate the
HRQoL burden [4, 5]. Providing physicians
and decision-makers with HRQoL data on the
facial redness of rosacea is therefore important
in the management of the disease, especially
since effective treatments for erythema of
rosacea currently exist.
The most recent Cochrane review on
interventions for rosacea listed change in
HRQoL as their first priority primary outcome,
highlighting the relevance of measuring HRQoL
in research and clinical practice [6]. In fact, of
the 106 articles in that Cochrane review, only
11 studies reported assessments of change in
quality of life following treatment for rosacea
[6]. HRQoL data has not always been collected
in a structured manner and a systematic review
found it was difficult to summarize HRQoL data
from rosacea studies due to the wide
heterogeneity of the studies [7]. A small pilot
study investigating the burden of the disease
among the various different types of rosacea
found that all subtypes had a relatively similar
negative impact on HRQoL [8]. However, only
two studies (38 patients in total) have been
identified reporting HRQoL data specifically in
patients with erythematotelangiectatic rosacea
[9, 10].
The aim of this meta-analysis was to analyze
the effect of facial erythema of rosacea on
HRQoL by pooling data from four
questionnaires (two validated generic and
dermatology-specific and two non-validated
rosacea and redness-specific questionnaires)
used in seven recent studies.
METHODS
Study Selection
A meta-analysis was performed on published
and unpublished baseline (before any
treatment) HRQoL data from previous
Galderma-sponsored studies. The
incorporation criteria were all studies that
generated HRQoL data using at least one of
the following questionnaires, including the
Euro QoL 5-dimension 3-level (EQ5D-3L),
Dermatology Life Quality Index (DLQI), the
Productivity and Social Life Questionnaire
(PSLQ) or Facial Redness Questionnaire (FRQ).
Data were available for a total of 1624 subjects
with erythema of rosacea from five randomized
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controlled trials [11–13], one open-label safety
study [14] and one epidemiological study [15].
HRQoL Instruments
Questionnaires used were the validated EQ5D
generic instrument applicable to a wide range of
health conditions: the validated ten-question
dermatology-specific DLQI instrument [16]; the
rosacea-specific PSLQ designed to assess the
effect on work and social life; and the
redness-specific FRQ [11]. The EQ-5D-3L
provided a simple descriptive profile of five
dimensions (mobility, self-care, usual activities,
pain/discomfort and anxiety/depression) with
three levels (no problems, some problems,
extreme problems). The respondent’s self-rated
health state was recorded on a vertical, visual
analog scale (VAS) (100 = best imaginable
health state).
Statistical Methods
The EQ-5D results for each of the three levels in
each of the five dimensions were converted into
a single summary index (where 0 = dead and
1.0 = full health) by applying the UK preference
weights. The DLQI questions had four possible
responses from not at all (0) to very much (3).
The DLQI total score was calculated by
summing the score of each question, resulting
in a maximum of 30 and a minimum of 0,
where a higher score represents worse quality of
life. In addition to the DLQI total score, six
domains were calculated and expressed as a
percentage of the maximum score: symptoms
and feelings, daily activities, leisure, work and
school, personal relationships and treatment.
To evaluate the impact due to erythema alone,
results were calculated for the subgroups of
subjects with and without lesions. To evaluate
the impact of self-perceived severe erythema of
rosacea, the DLQI total score was calculated for
subjects with moderate and severe patient
self-assessed (PSA) erythema. Analysis was
performed using SAS statistical software,
version 9.3 (SAS Institute Inc., Cary, NC, USA).
Compliance with Ethics Guidelines
This article is based on previously conducted
studies and does not involve any new studies of




Demographic data for subjects responding to
the questionnaires are summarized in Table 1.
Pooled baseline DLQI data was reported for 622
subjects with a mean age of 44.3 years: 74.3%
were women, 38.5% had C1 inflammatory
lesion and around three-quarters (74.8%) had
clinician-assessed moderate erythema (CEA)
(Table 1). A total of 92 subjects completed the
EQ5D and FRQ questionnaires with a mean age
of 54.1 years; 30.4% had inflammatory lesions
(a maximum of 5 inflammatory lesions were
allowed) and all subjects assessed their
erythema (PSA) as being severe (Table 1). The
PSLQ questionnaire was completed by 1002
subjects, the majority of whom had moderate
erythema based on either CEA (83.9%) or PSA
(84.9%) (Table 1).
EQ5D Questionnaire
Overall, the mean of the VAS was 74.0 out of
100 and the overall EQ5D single index score was
0.859 (Table 2).
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Table 1 Demographic data for subjects responding to the Euro QoL 5-dimension (EQ5D), Dermatology Life Quality
Index (DLQI), Productivity and Social Life (PSLQ), and Facial Redness (FRQ) Questionnaires
DLQI EQ5D/FRQ PSLQ
Gender
N 622 92 1002
Male 160 (25.7%) 36 (39.1%) 247 (24.7%)
Female 462 (74.3%) 56 (60.9%) 755 (75.3%)
Phototype
N 622 92 1002
I 73 (11.7%) 9 (9.8%) 86 (8.6%)
II 319 (51.3%) 61 (66.3%) 490 (48.9%)
III 201 (32.3%) 22 (23.9%) 328 (32.7%)




N 621 92 1002
Mean ± SD 44.3 ± 13.3 54.1 ± 12.8 49.4 ± 12.2
Median (min–max) 45.0 (18–79) 54.5 (19–79) 50.0 (18–87)
Baseline inﬂammatory lesions
N 361 92 1002
Yes 139 (38.5%) 28 (30.4%) 411 (41.0%)
Mean ± SD 0.7 ± 1.0 0.8 ± 1.5 2.7 ± 6.6
Median (min–max) 0.0 (0–5) 0.0 (0–5) 0.0 (0–55)
Baseline CEA
N 361 92 1002
3 =Moderate erythema; marked redness 270 (74.8%) 45 (48.9%) 841 (83.9%)
4 = Severe erythema; ﬁery redness 91 (25.2%) 47 (51.1%) 161 (16.1%)
Baseline PSA
N 361 92 1002
1 = Very mild redness 1 (0.1%)
2 =Mild redness 2 (0.2%)
3 =Moderate redness 225 (62.3%) – 851 (84.9%)
4 = Severe redness 136 (37.7%) 92 (100%) 148 (14.8%)
SD standard deviation, CEA clinician’s erythema assessment, PSA patient self-assessment of erythema, QoL quality of life
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Table 2 Euro QoL ﬁve-dimension (EQ-5D) Health Questionnaire overall for subjects with erythema of rosacea and with/
without inﬂammatory lesions
Baseline Without lesions With ‡1 lesion
Mobility
N 92 64 28
I have no problems in walking about 83 (90.2%) 57 (89.1%) 26 (92.9%)
I have some problems in walking about 9 (9.8%) 7 (10.9%) 2 (7.1%)
Self-care
N 92 64 28
I have no problems with self-care 91 (98.9%) 63 (98.4%) 28 (100.0%)
I have some problems washing or dressing myself 1 (1.1%) 1 (1.6%) 0 (0.0%)
Usual activities
N 92 64 28
I have no problems with performing my usual activities 82 (89.1%) 55 (85.9%) 27 (96.4%)
I have some problems with performing my usual activities 8 (8.7%) 7 (10.9%) 1 (3.6%)
I am unable to perform my usual activities 2 (2.2%) 2 (3.1%) 0 (0.0%)
Pain/discomfort
N 92 64 28
I have no pain or discomfort 63 (68.5%) 42 (65.6%) 21 (75.0%)
I have moderate pain or discomfort 27 (29.3%) 20 (31.3%) 7 (25.0%)
I have extreme pain or discomfort 2 (2.2%) 2 (3.1%) 0 (0.0%)
Anxiety/depression
N 91 63 28
I am not anxious or depressed 67 (73.6%) 44 (69.8%) 23 (82.1%)
I am moderately anxious or depressed 20 (22.0%) 15 (23.8%) 5 (17.9%)
I am extremely anxious or depressed 4 (4.4%) 4 (6.3%) 0 (0.0%)
Health state today (visual analog scale)
N 92 64 28
Mean ± SD 74.0 ± 17.7 72.3 ± 18.5 78.0 ± 15.5
Median (min–max) 80.0 (29–100) 79.0 (29–100) 80.0 (40–100)
Health state today (Single Summary Index—UK tariffs)
N 92 64 28
Mean ± SD 0.859 ± 0.199 0.832 ± 0.224 0.919 ± 0.108
Median (min–max) 1.000 (0.03–1.00) 0.848 (0.03–1.00) 1.000 (0.73–1.00)
SD standard deviation, QoL quality of life, EQ5D Euro QoL 5-dimension
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The most affected domains were pain/
discomfort (31.5% of subjects reported having
moderate or extreme pain) and anxiety/
depression (26.4% of subjects reported being
moderately or extremely anxious or depressed).
A worse mean health state was observed for
subjects without inflammatory lesions (72.3)
than in subjects with C1 lesion (78.0) and this
was the case across all domains (Table 2).
Similarly, the global EQ5D score was 0.832 for
subjects with no lesions (n = 64) and 0.919 for
subjects with at least one lesion (n = 28
subjects) (Table 2).
DLQI Questionnaire
The mean DLQI total score for the pooled data of
622 subjects was 6.2 points, indicating a
moderate influence of erythema of rosacea on
HRQoL. Almost half the subjects (43%) had at
least a moderate effect on their HRQoL and
19.8% of subjects had a total score of C11,
indicating severely impaired HRQoL (Fig. 1a).
Symptoms and feelings were the most affected
domain with a mean score of 2.3. The mean DLQI
scores expressed as a percentage of the maximum
score for each domain are shown in Fig. 2.
Subjects with a PSA of severe erythema of
rosacea had a worse mean total DLQI score than
moderate PSA subjects (8.6 vs 6.0) (see Fig. 1b
for an interpretation of the scores). Also,
subjects without inflammatory lesions had a
worse DLQI score than subjects with C1 lesion
(7.4 vs 6.3).
PSLQ
Of the subjects who worked, 11% indicated that
their rosacea had affected their productivity at
work (Table 3). Around a quarter of subjects
(26.1%) responded that they had avoided public
contact or canceled social engagements because
of their rosacea (Table 3).
FRQ
Of the 92 subjects, 79.4% were extremely,
moderately or somewhat self-conscious about
their facial redness (Fig. 3). In this population of
PSA severe subjects, almost two-thirds (62%)
and almost half (47.8%) reported that their
erythema of rosacea at least somewhat
interfered with their social life and work life,
respectively.
DISCUSSION
This pooled analysis incorporating data
collected from a total of 1624 subjects in seven
recent studies, using four questionnaires,
confirms that erythema of rosacea significantly
affects patients’ HRQoL. All HRQoL instruments
have conceptual limitations; hence we chose to
incorporate validated generic (EQ5D is very
widely used in health economic analyses) and
dermatology-specific (DLQI was the first HRQoL
instrument and is the most widely used)
questionnaires based on the quantity of
available data for comparison with other
diseases. Furthermore, to obtain a better sense
of what it is like to live with erythema of
rosacea, we also included the rosacea-specific
PSLQ and redness-specific FRQ questionnaires,
albeit non-validated questionnaires.
The EQ5D highlighted pain/discomfort and
anxiety/depression as the main drivers of
reduced HRQoL in rosacea subjects. Overall, the
mean EQ-5D scores (VAS 74.0 and index score
0.859) were similar to values reported for other
severe conditions. For comparison, a systematic
literature review of HRQoL in psoriasis reported
mean EQ-5D VAS scores ranging from 50.7 to
242 Dermatol Ther (Heidelb) (2016) 6:237–247
75.1 and mean EQ-5D utility index scores from
0.52 to 0.9 [17]. The authors concluded that
these values for patients with psoriasis
corresponded to the same level of deterioration
in HRQoL as for patients with other serious
chronic diseases, e.g., cardiovascular disease.
The relatively low EQ-5D HRQoL score for
erythema of rosacea may reflect the fact that all
the EQ-5D population subjects (100%) had
self-perceived severe erythema, which was
confirmed for around half of them (51.1%) by
a clinician’s assessment. Indeed, PSA severe
subjects had a worse mean DLQI score than
moderate PSA subjects (8.6 vs 6.0). Furthermore,
a systematic review exploring HRQoL in
patients with cutaneous rosacea identified an
association between negative impact on HRQoL
and disease severity [7].
Symptoms/feelings was the most impacted
DLQI domain. Overall, the mean DLQI total
Fig. 1 Erythema of rosacea: Dermatology Life Quality Index (DLQI) scores showing a the total score of the subjective
impact on patients’ lives and b patient self-assessment of moderate vs severe subjects. PSA patient self-assessment
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score of 6.2 points indicates a moderate
influence of erythema of rosacea on HRQoL.
This value is very similar to that in existing
literature since a review on 10 years of
experience with the DLQI reported a mean of
means of 6.7 for rosacea/rhinophyma [18]. This
score is lower than the mean of means reported
for psoriasis (8.8) or acne (11.9), but higher than
the scores for Darier’s disease (5.9) or
Hailey–Hailey disease (6.1) [18]. Two previous
studies in subjects exclusively with
erythematotelangiectatic rosacea reported
comparable DLQI scores of 5.6 and 7.8 [9, 10].
The subjects without lesions (EQ5D VAS of
72.3; EQ5D single index score of 0.83; DLQI
total score of 7.4) appeared to have even worse
HRQoL than subjects with C1 inflammatory
lesion (EQ5D VAS of 78; EQ5D single index score
of 0.92; DLQI total score of 6.3); patients may
thus be most concerned about the persistent
redness or erythema of rosacea rather than the
presence of inflammatory lesions.
Results of the non-validated disease-specific
PSLQ and redness-specific FRQ confirmed the
results observed with the validated
questionnaires. Rosacea was shown to affect
work life and social life using the PSLQ (subjects
mostly with moderate redness). An even larger
effect on work and social life was observed with
the FRQ in subjects with PSA severe redness.
Similarly, a large-scale international survey
Fig. 2 Erythema of rosacea: mean Dermatology Life Quality Index (DLQI) scores for each domain expressed as a
percentage of the total score
Table 3 Productivity and Social Life Questionnaire
(PSLQ) responses for subjects with erythema of rosacea
Baseline (N5 993)
Has your rosacea affected your productivity at work?
Signiﬁcantly 7 (0.7%)
Somewhat 75 (7.6%)
No effect 668 (67.3%)
Not applicable (do not work) 243 (24.5%)
Has your rosacea affected your normal daily activities?
Signiﬁcantly 19 (1.9%)
Somewhat 174 (17.5%)
No effect 800 (80.6%)
Avoided public contact or canceled social engagements
because of rosacea?
Yes 259 (26.1%)
Difﬁcult to establish new relationships because of rosacea?
Yes 140 (14.1%)
Inhibited your social life?
Yes 240 (24.2%)
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showed that erythema of rosacea can lead to
stigmatization, as well as having an impact on
emotional and psychological well-being [19].
Treatments for the persistent redness of
rosacea, e.g., brimonidine 0.33% gel (3.3 mg/g)
[11–14, 20, 21] and laser and intense-pulsed
light [9, 10], have been reported to improve
patients’ HRQoL [22]. However, despite the
availability of effective treatments, many
rosacea patients are underdiagnosed,
misdiagnosed and undertreated [15]. It appears
that patients do not always seek medical advice
[23], may be unable to successfully convey the
impact on HRQoL and/or clinicians may
overlook the psychological impact. A possible
explanation for this may be that physicians
have limited time during a consultation for
effective communication and do not encourage
patients to express their views [24, 25].
The use of HRQoL instruments in clinical
practice, combined with effective
patient–physician communication, should
help facilitate dialog between physicians and
patients, so that treatment decisions can be
based on the patient’s priorities and
preferences informed by best medical
evidence [25–28].
Recommendations have been developed to
help the introduction of HRQoL tools into
clinical practice and new technology may be
able to address many of the practical problems
associated with measuring HRQoL in clinical
practice [28].
A possible limitation of this meta-analysis is
that it was not from a systematic review of the
literature. However, it was a pooled analysis of
seven existing studies and included published and
unpublished data that met our incorporation
criteria (data from one of the four
questionnaires) to avoid publication bias. It is
noteworthy that the EQ5D and FRQ data were
from a single study (n = 92 subjects), in which the
maximum number of lesions allowed was limited
to five [11]. Although subjects participating in
clinical studies may not be representative of the
general population [11–14] (except for subjects in
the epidemiological study [15]), an advantage of
these subjects is that they all had a confirmed
diagnosis of rosacea.
CONCLUSION
This meta-analysis demonstrated that erythema of
rosacea causes a marked decrease in HRQoL,
Fig. 3 Erythema of rosacea: Facial Redness Questionnaire (FRQ) responses
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especially in subjects with self-perceived severe
erythema. Patients without inflammatory lesions
may be even more concerned about the persistent
redness or erythema of rosacea than those with
inflammatory lesions. The results highlight the
need for medical intervention to treat the
symptoms of erythema of rosacea and improve
patients’ well-being.
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